Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Bullish On Diabetes/Oncology Products; Analysts Skeptical

This article was originally published in The Pink Sheet Daily

Executive Summary

The Indianapolis-based big pharma touted the value of its late-stage pipeline at an analyst meeting on Oct. 3, particularly its diabetes and oncology franchises, even though they face tough competition and have encountered some setbacks.

You may also be interested in...



Emerging Markets Earnings Roundup: Eli Lilly, Roche (Part 4)

Eli Lilly says emerging markets remain a growing focus as it navigates sliding sales for key products in developed markets due to patent expirations. Roche looks to patient access programs again as biosimilar competition threats grow.

South Korea’s Hanmi Opens Global Trials Of Monthly Dose GLP-1 Biosimilar

Hanmi hopes to differentiate its type 2 diabetes Byetta biosimilar with once-a-month administration.

Lilly Gets Ready To Compete With Its Late-Stage Diabetes Pipeline

The Indianapolis-based pharma highlighted the Phase III results from two of its most promising pipeline candidates at ADA. The company is preparing to have four new diabetes drugs on the market by 2016, including two basal insulins, a GLP-1 agonist and a SGLT-2 inhibitor.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel